What happened
Eos SENOLYTIX reported interim data from an aged-rat study of its MitoXcel geropeptide PTC-2105. The company says the results showed preserved physical function in a second species.
Plain-English summary written by an AI model from the Business Insider story's headline and teaser only (Business Insider doesn't let automated readers open its pages).
The original
- Headline
- Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study
- From
- Business Insider (news report)
- Published
- Oct 30, 2026